| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 8.83M | 11.61M | 233.16M | 375.2M | 485.42M | 38.02M | 28.83M |
| Revenue Growth % | - | 0.31% | 19.08% | 0.61% | 0.29% | -0.92% | -0.24% |
| Cost of Goods Sold | 5.8M | 0 | 27.14M | 45.52M | 66.44M | 0 | 0 |
| COGS % of Revenue | 0.66% | - | 0.12% | 0.12% | 0.14% | - | - |
| Gross Profit | 3.03M | 11.61M | 206.01M | 329.69M | 418.99M | 38.02M | 28.83M |
| Gross Margin % | 0.34% | 1% | 0.88% | 0.88% | 0.86% | 1% | 1% |
| Gross Profit Growth % | - | 2.83% | 16.74% | 0.6% | 0.27% | -0.91% | -0.24% |
| Operating Expenses | 7.99M | 15.73M | 49.98M | 125.27M | 202.48M | 275.23M | 343.6M |
| OpEx % of Revenue | 0.9% | 1.35% | 0.21% | 0.33% | 0.42% | 7.24% | 11.92% |
| Selling, General & Admin | 2.86M | 4.01M | 15.75M | 48.76M | 66.75M | 75.18M | 85.49M |
| SG&A % of Revenue | 0.32% | 0.35% | 0.07% | 0.13% | 0.14% | 1.98% | 2.97% |
| Research & Development | 5.8M | 10.11M | 29.39M | 62.06M | 107.88M | 175.66M | 167.26M |
| R&D % of Revenue | 0.66% | 0.87% | 0.13% | 0.17% | 0.22% | 4.62% | 5.8% |
| Other Operating Expenses | -675.51K | 1.6M | 4.84M | 14.45M | 27.84M | 24.39M | 90.85M |
| Operating Income | -753K | -4.12M | 156.03M | 204.41M | 216.51M | -237.21M | -314.77M |
| Operating Margin % | -0.09% | -0.35% | 0.67% | 0.54% | 0.45% | -6.24% | -10.92% |
| Operating Income Growth % | - | -4.47% | 38.9% | 0.31% | 0.06% | -2.1% | -0.33% |
| EBITDA | 165.46K | -2.27M | 161.3M | 221.66M | 249.61M | -206.31M | -217.77M |
| EBITDA Margin % | 0.02% | -0.2% | 0.69% | 0.59% | 0.51% | -5.43% | -7.55% |
| EBITDA Growth % | - | -14.72% | 72.06% | 0.37% | 0.13% | -1.83% | -0.06% |
| D&A (Non-Cash Add-back) | 918.46K | 1.85M | 5.27M | 17.25M | 33.1M | 30.89M | 97M |
| EBIT | 521K | -2M | 164.34M | 221.9M | 227.06M | -223.05M | -301.15M |
| Net Interest Income | -170K | -54K | -6.22M | -1.9M | 12.03M | 42.25M | 38.47M |
| Interest Income | 42K | 155K | 293K | 3.33M | 16.08M | 42.25M | 38.47M |
| Interest Expense | 212K | 209K | 6.51M | 5.22M | 4.04M | 0 | 0 |
| Other Income/Expense | 1.06M | 1.91M | 1.8M | 14.74M | 22.59M | 63.18M | 114.37M |
| Pretax Income | 309K | -2.21M | 157.83M | 219.15M | 239.1M | -174.03M | -200.4M |
| Pretax Margin % | 0.03% | -0.19% | 0.68% | 0.58% | 0.49% | -4.58% | -6.95% |
| Income Tax | 0 | 0 | 38.91M | 65.69M | 80.58M | -27.63M | -37.54M |
| Effective Tax Rate % | 1% | 1% | 0.75% | 0.7% | 0.66% | 0.84% | 0.81% |
| Net Income | 309K | -2.21M | 118.92M | 153.46M | 158.52M | -146.4M | -162.86M |
| Net Margin % | 0.03% | -0.19% | 0.51% | 0.41% | 0.33% | -3.85% | -5.65% |
| Net Income Growth % | - | -8.16% | 54.78% | 0.29% | 0.03% | -1.92% | -0.11% |
| Net Income (Continuing) | 309K | -2.21M | 118.92M | 153.46M | 158.52M | -146.4M | -162.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00 | -0.01 | 0.45 | 0.48 | 0.50 | -0.51 | -0.55 |
| EPS Growth % | - | - | 44.69% | 0.07% | 0.04% | -2.02% | -0.08% |
| EPS (Basic) | 0.00 | -0.01 | 0.32 | 0.56 | 0.56 | -0.51 | -0.55 |
| Diluted Shares Outstanding | 151.04M | 237.72M | 263.13M | 318.29M | 314.83M | 289.17M | 294.33M |
| Basic Shares Outstanding | 151.06M | 215.41M | 267.82M | 275.76M | 285.06M | 289.17M | 294.33M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.16M | 12.64M | 813.33M | 929.8M | 1.03B | 871.99M | 751.37M |
| Cash & Short-Term Investments | 10.44M | 7.55M | 594.12M | 722.98M | 886.49M | 760.59M | 625.61M |
| Cash Only | 10.44M | 7.55M | 594.12M | 476.14M | 386.54M | 133.32M | 156.32M |
| Short-Term Investments | 0 | 0 | 0 | 246.84M | 499.95M | 627.26M | 469.29M |
| Accounts Receivable | 1.4M | 2.12M | 213.73M | 160.58M | 38.59M | 64.38M | 92.13M |
| Days Sales Outstanding | 58.05 | 66.76 | 334.59 | 156.21 | 29.02 | 618 | 1.17K |
| Inventory | 0 | 163K | 1.41M | 1.67M | 1.53M | 1.11M | 0 |
| Days Inventory Outstanding | - | - | 18.93 | 13.41 | 8.42 | - | - |
| Other Current Assets | 2.76M | 2.25M | 0 | 39.28M | 89.82M | 45.91M | 33.63M |
| Total Non-Current Assets | 6.33M | 10.85M | 192.21M | 388.77M | 515.42M | 616.11M | 609.18M |
| Property, Plant & Equipment | 6.33M | 8.48M | 17.92M | 111.62M | 217.25M | 287.7M | 340.43M |
| Fixed Asset Turnover | 1.40x | 1.37x | 13.01x | 3.36x | 2.23x | 0.13x | 0.08x |
| Goodwill | 0 | 0 | 31.5M | 47.81M | 47.81M | 47.81M | 47.81M |
| Intangible Assets | 0 | 0 | 115.15M | 148.39M | 131.5M | 120.42M | 42.11M |
| Long-Term Investments | 0 | 0 | 20.03M | 50.31M | 72.52M | 65.94M | 82.3M |
| Other Non-Current Assets | 0 | 2.37M | 1.71M | 23.23M | 41.03M | 94.24M | 96.54M |
| Total Assets | 21.49M | 23.49M | 1.01B | 1.32B | 1.54B | 1.49B | 1.36B |
| Asset Turnover | 0.41x | 0.49x | 0.23x | 0.28x | 0.32x | 0.03x | 0.02x |
| Asset Growth % | - | 0.09% | 41.81% | 0.31% | 0.17% | -0.03% | -0.09% |
| Total Current Liabilities | 6.43M | 7.89M | 103.49M | 120.68M | 118.32M | 119.01M | 76.61M |
| Accounts Payable | 1.52M | 1.64M | 7.32M | 14.92M | 14.83M | 25.51M | 34.35M |
| Days Payables Outstanding | 95.49 | - | 98.43 | 119.68 | 81.47 | - | - |
| Short-Term Debt | 2.53M | 2.47M | 190K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 50.12K | 3.37M | 9.08M | 54.85M | 69.84M | 60.68M | 8.09M |
| Current Ratio | 2.36x | 1.60x | 7.86x | 7.70x | 8.67x | 7.33x | 9.81x |
| Quick Ratio | 2.36x | 1.58x | 7.85x | 7.69x | 8.65x | 7.32x | 9.81x |
| Cash Conversion Cycle | - | - | 255.09 | 49.94 | -44.03 | - | - |
| Total Non-Current Liabilities | 3.45M | 5.34M | 71.54M | 172.16M | 189.31M | 216.76M | 227.86M |
| Long-Term Debt | 911.22K | 1.36M | 2.2M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 2.64M | 3.71M | 36.41M | 76.67M | 71.22M | 60.74M |
| Deferred Tax Liabilities | 0 | 0 | 26.16M | 37.37M | 33.18M | 30.61M | 10.05M |
| Other Non-Current Liabilities | 277.13K | 1.34M | 13.57M | 37.62M | 19.14M | 10.82M | 1.47M |
| Total Liabilities | 9.88M | 13.24M | 175.03M | 292.84M | 307.63M | 335.78M | 304.47M |
| Total Debt | 3.44M | 6.89M | 6.78M | 40.06M | 82.26M | 77.38M | 65.36M |
| Net Debt | -7M | -662K | -587.34M | -436.08M | -304.28M | -55.94M | -90.96M |
| Debt / Equity | 0.30x | 0.67x | 0.01x | 0.04x | 0.07x | 0.07x | 0.06x |
| Debt / EBITDA | 20.81x | - | 0.04x | 0.18x | 0.33x | - | - |
| Net Debt / EBITDA | -42.32x | - | -3.64x | -1.97x | -1.22x | - | - |
| Interest Coverage | -3.55x | -19.70x | 23.96x | 39.12x | 53.53x | - | - |
| Total Equity | 11.61M | 10.25M | 830.51M | 1.03B | 1.23B | 1.15B | 1.06B |
| Equity Growth % | - | -0.12% | 80.01% | 0.24% | 0.2% | -0.07% | -0.08% |
| Book Value per Share | 0.08 | 0.04 | 3.16 | 3.22 | 3.92 | 3.98 | 3.59 |
| Total Shareholders' Equity | 11.61M | 10.25M | 830.51M | 1.03B | 1.23B | 1.15B | 1.06B |
| Common Stock | 5.07M | 5.12M | 710.39M | 722.43M | 734.37M | 753.2M | 777.17M |
| Retained Earnings | -2.5M | -4.72M | 114.2M | 267.67M | 426.19M | 279.79M | 116.93M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 280K | -1.39M | -1.72M | -4.38M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 3.56M | 2.69M | 22.69M | 244.58M | 277.36M | -43.88M | -108.56M |
| Operating CF Margin % | 0.4% | 0.23% | 0.1% | 0.65% | 0.57% | -1.15% | -3.76% |
| Operating CF Growth % | - | -0.24% | 7.42% | 9.78% | 0.13% | -1.16% | -1.47% |
| Net Income | 309K | -2.21M | 118.92M | 153.46M | 158.52M | -146.4M | -162.86M |
| Depreciation & Amortization | 918K | 1.85M | 5.27M | 17.25M | 33.1M | 30.89M | 97M |
| Stock-Based Compensation | 615K | 890K | 8.4M | 0 | 49.48M | 64.18M | 67.58M |
| Deferred Taxes | 0 | 0 | 2.1M | -2.02M | -2.11M | 1.96M | 0 |
| Other Non-Cash Items | -188K | 194K | 4.71M | 34.22M | 8.55M | -7.74M | -84.44M |
| Working Capital Changes | 1.91M | 1.97M | -116.7M | 41.67M | 29.82M | 13.22M | -25.84M |
| Change in Receivables | -477K | -1.8M | -203.02M | 22.48M | -22.71M | -45.93M | -75.12M |
| Change in Inventory | -897.77K | 0 | 0 | 0 | 0 | 18.25M | 0 |
| Change in Payables | 180K | 150K | 6.6M | 1.4M | 1.07M | -15.1M | 10.63M |
| Cash from Investing | -5.31M | -5.78M | -119.78M | -332.25M | -352.63M | -221.11M | 121.41M |
| Capital Expenditures | -5.31M | -4M | -9.67M | -58.45M | -72.66M | -77.51M | -78.4M |
| CapEx % of Revenue | 0.6% | 0.34% | 0.04% | 0.16% | 0.15% | 2.04% | 2.72% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | -1.78M | -3.22M | 32.62M | 16.43M | 25.31M | 35.71M |
| Cash from Financing | 12.19M | 195K | 683.65M | -3.89M | -1.63M | 10.36M | 12.77M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 37K | 25K | 1M | -7.55M | -4.38M | -1.23M | -729K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -1.74M | -1.3M | 8.02M | 186.13M | 204.7M | -121.38M | -186.95M |
| FCF Margin % | -0.2% | -0.11% | 0.03% | 0.5% | 0.42% | -3.19% | -6.48% |
| FCF Growth % | - | 0.25% | 7.15% | 22.22% | 0.1% | -1.59% | -0.54% |
| FCF per Share | -0.01 | -0.01 | 0.03 | 0.58 | 0.65 | -0.42 | -0.64 |
| FCF Conversion (FCF/Net Income) | 11.54x | -1.22x | 0.19x | 1.59x | 1.75x | 0.30x | 0.67x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 2.66% | -20.23% | 28.29% | 16.53% | 14.03% | -12.27% | -14.75% |
| Return on Invested Capital (ROIC) | - | -43.5% | 92.6% | 36.82% | 21.39% | -17.57% | -22.9% |
| Gross Margin | 34.29% | 100% | 88.36% | 87.87% | 86.31% | 100% | 100% |
| Net Margin | 3.5% | -19.04% | 51% | 40.9% | 32.66% | -385% | -564.83% |
| Debt / Equity | 0.30x | 0.67x | 0.01x | 0.04x | 0.07x | 0.07x | 0.06x |
| Interest Coverage | -3.55x | -19.70x | 23.96x | 39.12x | 53.53x | - | - |
| FCF Conversion | 11.54x | -1.22x | 0.19x | 1.59x | 1.75x | 0.30x | 0.67x |
| Revenue Growth | - | 31.49% | 1907.88% | 60.92% | 29.38% | -92.17% | -24.17% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Research Fees | 19.08M | 40.8M | 35.56M | 26.28M |
| Research Fees Growth | - | 113.89% | -12.86% | -26.08% |
| Milestone Payments | 8M | 900K | 1.5M | 1.5M |
| Milestone Payments Growth | - | -88.75% | 66.67% | 0.00% |
| License | 20.78M | 696K | 969K | 1.05M |
| License Growth | - | -96.65% | 39.22% | 8.26% |
| Royalty | 327.3M | 443M | - | - |
| Royalty Growth | - | 35.35% | - | - |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| CANADA | 353.4M | 484.2M | 36M | 26.2M |
| CANADA Growth | - | 37.01% | -92.57% | -27.22% |
| UNITED STATES | 21.8M | 1.2M | 2M | 2.7M |
| UNITED STATES Growth | - | -94.50% | 66.67% | 35.00% |
AbCellera Biologics Inc. (ABCL) reported $35.3M in revenue for fiscal year 2024. This represents a 300% increase from $8.8M in 2018.
AbCellera Biologics Inc. (ABCL) saw revenue decline by 24.2% over the past year.
AbCellera Biologics Inc. (ABCL) reported a net loss of $171.7M for fiscal year 2024.
AbCellera Biologics Inc. (ABCL) has a return on equity (ROE) of -14.7%. Negative ROE indicates the company is unprofitable.
AbCellera Biologics Inc. (ABCL) had negative free cash flow of $153.1M in fiscal year 2024, likely due to heavy capital investments.